Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Haemophilia

M R Cahill1, B T Colvin

  • 1Haemophilia Comprehensive Care Centre, Royal London Hospital, Whitechapel, UK.

Postgraduate Medical Journal
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Advances in understanding haemophilia genetics and recombinant factor technology have improved patient care. However, viral infections and inhibitor development remain significant challenges, necessitating comprehensive care centers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Strategies to Reduce Inappropriate Laboratory Testing.

Irish medical journal·2024
Same author

CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment.

Clinical lymphoma, myeloma & leukemia·2022
Same author

CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study.

Blood advances·2019
Same author

General practitioner views on the determinants of test ordering: a theory-based qualitative approach to the development of an intervention to improve immunoglobulin requests in primary care.

Implementation science : IS·2016
Same author

Current Practice in the Treatment of Haemophilia.

Hematology (Amsterdam, Netherlands)·2016
Same author

Clinical experience with a purified factor IX concentrate (Replenine).

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same journal

Two cases of toxic epidermal necrolysis with severe ocular involvement treated with adjunctive tofacitinib.

Postgraduate medical journal·2026
Same journal

Diastolic dysfunction and diabetes: the DIADAD study-a retrospective cohort study from Liverpool.

Postgraduate medical journal·2026
Same journal

Care, cash, and proof: forensic accountability for war-related starvation.

Postgraduate medical journal·2026
Same journal

Response to traumatic injuries in polo players in England.

Postgraduate medical journal·2026
Same journal

Aids to venesection and parenteral drug administration in patients with difficult veins.

Postgraduate medical journal·2026
Same journal

Diagnostic reasoning in clinical neurology: a comprehensive primer.

Postgraduate medical journal·2026
See all related articles

Area of Science:

  • Hematology
  • Genetics
  • Virology

Background:

  • Haemophilia, an X-linked bleeding disorder, has a long history, but its molecular genetics understanding is recent.
  • Significant improvements in patient lifespan and quality of life occurred in the 1980s, but HIV and Hepatitis C infections posed major threats.
  • DNA inversion in the X chromosome was identified as a cause for severe haemophilia A.

Purpose of the Study:

  • To review the historical understanding and recent molecular genetic discoveries in haemophilia.
  • To discuss the impact of viral infections (HIV, Hepatitis C) on haemophilia patient care.
  • To highlight advancements in treatment, including recombinant factor concentrates and the importance of comprehensive care.

Main Methods:

  • Literature review of haemophilia genetics, treatment advancements, and patient care.

Related Experiment Videos

  • Analysis of historical data on patient outcomes and causes of mortality.
  • Discussion of current challenges and future directions in haemophilia management.

    • Main Results:

    • Molecular genetics has elucidated diverse DNA defects in haemophilia, including X chromosome inversions.
    • Viral contamination of clotting factors led to widespread HIV and Hepatitis C infections in patients treated before 1985.
    • Recombinant DNA technology has produced safer factor VIII and factor IX concentrates.
    • Inhibitor development to factor concentrates remains a serious complication.
    • Prophylactic treatment preserves joint function in severe haemophilia patients.

    Conclusions:

    • Comprehensive care centers are crucial for managing the multifaceted needs of severe haemophilia patients.
    • Continued research and development are essential to address complications like inhibitor development and to find curative treatments.
    • Advancements in recombinant technology and processing techniques have significantly improved the safety of clotting factor concentrates.